Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Calgary

$17,500.00

Determining non-tumour contributions to antiviral immunity against oncolytic virus Myxoma in glioma models and brain tumour initiating cells

FY 2009-10

Summary
Glioma is a type of human brain cancer which is highly invasive and almost uniformly fatal. The mean prognosis of only a single year has not changed significantly in the last three decades, prompting significant investigation into new treatments. It has been shown that the virus 'Myxoma', which normally infects only rabbits, can also selectively target and kill gliomal cancer cells in mice lacking an immune system. This novel viral cancer therapy has shown great promise, but continues to be limited by immune system interference. Our aim is to determine which specific molecular elements of the immune system are inhibiting viral cancer therapy. In doing so, we hope to develop a selective, effective and safe combination treatment which optimizes viral cancer therapy, with minimal effect on the body's immune system. Through expanding our knowledge and understanding of the molecular mechanisms in a mouse model, we hope to reveal the clinical potential of this promising new therapeutic.
Program
Master's Award: Canada Graduate Scholarships
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
199709
Name
McKenzie Brienne A
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Canada Graduate Scholarships Master's Awards A
Projecttitle
Determining non-tumour contributions to antiviral immunity against oncolytic virus Myxoma in glioma models and brain tumour initiating cells
Programtype2
Studentship Programs
Orgnameinp2
University of Calgary
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Brain Cancer (Glioma); Brain Tumour Initiating/Stem Cells; Neuroimmunology; Oncolytic Virotherapy
Abstract
Glioma is a type of human brain cancer which is highly invasive and almost uniformly fatal. The mean prognosis of only a single year has not changed significantly in the last three decades, prompting significant investigation into new treatments. It has been shown that the virus 'Myxoma', which normally infects only rabbits, can also selectively target and kill gliomal cancer cells in mice lacking an immune system. This novel viral cancer therapy has shown great promise, but continues to be limited by immune system interference. Our aim is to determine which specific molecular elements of the immune system are inhibiting viral cancer therapy. In doing so, we hope to develop a selective, effective and safe combination treatment which optimizes viral cancer therapy, with minimal effect on the body's immune system. Through expanding our knowledge and understanding of the molecular mechanisms in a mouse model, we hope to reveal the clinical potential of this promising new therapeutic.
Competitiondate
201002
Approvedterm2
1 yr 0 mth
Pinamesdelim
McKenzie, Brienne A
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~